These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23921550)

  • 1. MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.
    Jin HY; Oda H; Lai M; Skalsky RL; Bethel K; Shepherd J; Kang SG; Liu WH; Sabouri-Ghomi M; Cullen BR; Rajewsky K; Xiao C
    EMBO J; 2013 Aug; 32(17):2377-91. PubMed ID: 23921550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myc suppression of Nfkb2 accelerates lymphomagenesis.
    Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
    BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
    Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
    Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1.
    Contreras JR; Palanichamy JK; Tran TM; Fernando TR; Rodriguez-Malave NI; Goswami N; Arboleda VA; Casero D; Rao DS
    Oncotarget; 2015 May; 6(13):11023-37. PubMed ID: 25906746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis.
    Ding L; Zhang Y; Han L; Fu L; Mei X; Wang J; Itkow J; Elabid AEI; Pang L; Yu D
    Oncogene; 2018 Mar; 37(10):1293-1307. PubMed ID: 29284789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.
    Schneider C; Setty M; Holmes AB; Maute RL; Leslie CS; Mussolin L; Rosolen A; Dalla-Favera R; Basso K
    Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8185-90. PubMed ID: 24843176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent PI3K and NF-κB activation drives B-cell lymphomagenesis.
    Jin HY; Lai M; Shephard J; Xiao C
    Leukemia; 2016 Nov; 30(11):2267-2270. PubMed ID: 27451974
    [No Abstract]   [Full Text] [Related]  

  • 8. MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas.
    Jeong D; Kim J; Nam J; Sun H; Lee YH; Lee TJ; Aguiar RC; Kim SW
    Leukemia; 2015 Sep; 29(9):1868-74. PubMed ID: 25915824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.
    Sander S; Calado DP; Srinivasan L; Köchert K; Zhang B; Rosolowski M; Rodig SJ; Holzmann K; Stilgenbauer S; Siebert R; Bullinger L; Rajewsky K
    Cancer Cell; 2012 Aug; 22(2):167-79. PubMed ID: 22897848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes.
    Xiao C; Srinivasan L; Calado DP; Patterson HC; Zhang B; Wang J; Henderson JM; Kutok JL; Rajewsky K
    Nat Immunol; 2008 Apr; 9(4):405-14. PubMed ID: 18327259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-19 is a key oncogenic component of mir-17-92.
    Olive V; Bennett MJ; Walker JC; Ma C; Jiang I; Cordon-Cardo C; Li QJ; Lowe SW; Hannon GJ; He L
    Genes Dev; 2009 Dec; 23(24):2839-49. PubMed ID: 20008935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.
    De Falco G; Ambrosio MR; Fuligni F; Onnis A; Bellan C; Rocca BJ; Navari M; Etebari M; Mundo L; Gazaneo S; Facchetti F; Pileri SA; Leoncini L; Piccaluga PP
    BMC Cancer; 2015 Oct; 15():668. PubMed ID: 26453442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.
    Varano G; Raffel S; Sormani M; Zanardi F; Lonardi S; Zasada C; Perucho L; Petrocelli V; Haake A; Lee AK; Bugatti M; Paul U; Van Anken E; Pasqualucci L; Rabadan R; Siebert R; Kempa S; Ponzoni M; Facchetti F; Rajewsky K; Casola S
    Nature; 2017 Jun; 546(7657):302-306. PubMed ID: 28562582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis.
    Vaira V; Gaudioso G; Laginestra MA; Terrasi A; Agostinelli C; Bosari S; Di Sabatino A; Vanoli A; Paulli M; Ferrero S; Roncoroni L; Lombardo V; Perera LP; Fabris S; Vecchi M; Pileri S; Elli L
    Clin Sci (Lond); 2020 May; 134(10):1151-1166. PubMed ID: 32420596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
    Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
    Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.
    Mazzoccoli L; Robaina MC; Apa AG; Bonamino M; Pinto LW; Queiroga E; Bacchi CE; Klumb CE
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):483-497. PubMed ID: 29318382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
    Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
    Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction and verification of target of helenalin against hepatic stellate cell activation based on miR-200a-mediated PI3K/Akt and NF-κB pathways.
    Fang B; Wen S; Li Y; Bai F; Wei Y; Xiong Y; Huang Q; Lin X
    Int Immunopharmacol; 2021 Mar; 92():107208. PubMed ID: 33444919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-155 regulates HGAL expression and increases lymphoma cell motility.
    Dagan LN; Jiang X; Bhatt S; Cubedo E; Rajewsky K; Lossos IS
    Blood; 2012 Jan; 119(2):513-20. PubMed ID: 22096245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
    Ramírez-Moya J; Wert-Lamas L; Santisteban P
    Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.